The rate of anti-CD19 antibody uptake therefore does correlate with the efficacy of the anti-CD19-MCC-DM1 conjugate in vitro, and implies that such conjugates may be more effective at treating CD21− or CD21lo CD19+ tumours in vivo. Here, CD19 is linked to neoplasm.